Skip to Menu Skip to Search Contact Us Skip to Content
US Flag

You are accessing SGS’s website from the USA.

Visit the US website instead

Stay on the global website and remember my choice

Nitrosamine Control: Understanding the New FDA and EMA Regulations

After their detection in 2018, nitrosamines have been a pressing topic in the pharmaceutical world.

With major regulatory updates introduced by the FDA and EMA, all pharmaceutical manufacturers have been instructed to conduct a risk assessment and proactively test their products for the presence of nitrosamines. It’s therefore crucial for pharmaceutical companies and manufacturers to get up to speed with these latest requirements.

In this technical bulletin, we provide more details on the three-step risk assessment proposed to comply with FDA & EMA methods.

Please complete the form to download your copy.

Fields marked with an asterisk (*) are mandatory.

White paper request form

Are you an SGS client?*

200 characters remaining